Kenneth Galbraith, Zymeworks CEO
Zymeworks shows positive — yet early — pivotal data in bile duct cancers, plans accelerated approval run
Zymeworks is showing off some new topline data on its HER2 bispecific antibody — after showcasing a positive data turnout at ASCO earlier in 2022. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.